A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
Public ClinicalTrials.gov record NCT06907875. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients
Study identification
- NCT ID
- NCT06907875
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 2025
- Primary completion
- Mar 30, 2031
- Completion
- Apr 29, 2032
- Last update posted
- Apr 21, 2026
2025 – 2032
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| David Geffen School of Medicine at University of California, Los Angeles | Los Angeles | California | 90095 | Recruiting |
| Rare Disease Research | Atlanta | Georgia | 303329 | Recruiting |
| Kennedy Krieger Institute, Center for Genetic Muscle Disorders | Baltimore | Maryland | 21205 | Recruiting |
| University of Massachusetts Chan Medical School | Worcester | Massachusetts | 01605 | Recruiting |
| Utah Program for Inherited Neuromuscular Disorders - University of Utah | Salt Lake City | Utah | 84112 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
Recently updated Facioscapulohumeral Muscular Dystrophy trials
Other public records listing Facioscapulohumeral Muscular Dystrophy. Sorted by last update posted; newest first. Not a recommendation.
- NCT07435129: Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD Recruiting
- NCT03458832: Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD Active, not recruiting
- NCT07409142: BetterLife FSHD: A Patient-driven Health and Research Platform Recruiting
- NCT07038200: A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD Recruiting
- NCT05019625: Biomarker Development for Muscular Dystrophies Recruiting
- NCT00082108: Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06907875, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06907875 live on ClinicalTrials.gov.